These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23370212)

  • 1. Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer.
    Meng F; Sun G; Zhong M; Yu Y; Brewer MA
    Br J Cancer; 2013 Feb; 108(3):579-86. PubMed ID: 23370212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.
    Meng F; Sun G; Zhong M; Yu Y; Brewer MA
    Int J Oncol; 2013 Aug; 43(2):495-502. PubMed ID: 23709006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells.
    Mateen S; Raina K; Agarwal C; Chan D; Agarwal R
    J Pharmacol Exp Ther; 2013 May; 345(2):206-14. PubMed ID: 23461975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sodium butyrate and cisplatin on expression of EMT markers.
    Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
    PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer.
    Zhang YW; Zheng Y; Wang JZ; Lu XX; Wang Z; Chen LB; Guan XX; Tong JD
    Epigenetics; 2014 Jun; 9(6):896-909. PubMed ID: 24699858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
    Chang YW; Singh KP
    PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
    El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
    Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
    Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
    PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
    Chou JL; Su HY; Chen LY; Liao YP; Hartman-Frey C; Lai YH; Yang HW; Deatherage DE; Kuo CT; Huang YW; Yan PS; Hsiao SH; Tai CK; Lin HJ; Davuluri RV; Chao TK; Nephew KP; Huang TH; Lai HC; Chan MW
    Lab Invest; 2010 Mar; 90(3):414-25. PubMed ID: 20065949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
    Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
    Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
    Zhang J; Wang W; Qian L; Zhang Q; Lai D; Qi C
    Oncol Rep; 2015 Nov; 34(5):2375-84. PubMed ID: 26323892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
    Bovenzi V; Momparler RL
    Cancer Chemother Pharmacol; 2001 Jul; 48(1):71-6. PubMed ID: 11488527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
    Scholpa NE; Kolli RT; Moore M; Arnold RD; Glenn TC; Cummings BS
    Chem Biol Interact; 2016 Oct; 258():21-9. PubMed ID: 27543423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.
    Drzewiecka H; Gałęcki B; Jarmołowska-Jurczyszyn D; Kluk A; Dyszkiewicz W; Jagodziński PP
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):1927-46. PubMed ID: 27393180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morin exerts anti-metastatic, anti-proliferative and anti-adhesive effect in ovarian cancer cells: an in vitro studies.
    Nowak E; Sypniewski D; Bednarek I
    Mol Biol Rep; 2020 Mar; 47(3):1965-1978. PubMed ID: 32020427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.